These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6418264)

  • 41. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
    Matzkin H; Lewyshon O; Ayalon D; Braf Z
    Cancer; 1989 Apr; 63(7):1287-91. PubMed ID: 2465816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination treatment in M1 prostate cancer.
    Ferrari P; Castagnetti G; Ferrari G; Pollastri CA; Tavoni F; Dotti A
    Cancer; 1993 Dec; 72(12 Suppl):3880-5. PubMed ID: 8252509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term results with the Gn-RH analogue, buserelin, in metastatic prostate cancer.
    Maffezzini M; Villa E; Broglia L; Francesca F; Rigatti P
    Tumori; 1990 Feb; 76(1):66-8. PubMed ID: 2108517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH; Wenderoth UK; Ehrenthal W; von Wallenberg H; Spindler HW; Hohenfellner R
    Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acne conglobata responding to buserelin, a gonadotrophin-releasing hormone analogue.
    Waxman J; Rustin MH; Perry L; Kirby JD
    Br J Dermatol; 1983 Dec; 109(6):679-81. PubMed ID: 6228245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 47. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J
    Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
    [No Abstract]   [Full Text] [Related]  

  • 49. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 51. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
    Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
    Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
    Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
    Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
    Presant CA; Soloway MS; Klioze SS; Yakabow A; Presant SN; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Todd B
    Cancer; 1987 May; 59(10):1713-6. PubMed ID: 3103904
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
    Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
    Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 60. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.
    Siegel YI; Korczak D; Lindner A
    Eur Urol; 1991; 19(1):16-8. PubMed ID: 1901042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.